αvβ3–Targeted nanotherapy suppresses inflammatory arthritis in mice
Open Access
- 15 April 2009
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 23 (9) , 2978-2985
- https://doi.org/10.1096/fj.09-129874
Abstract
The purpose of this study was to assess whether an alternative treatment approach that targets angiogenesis, delivered through ligand-targeted nanotherapy, would ameliorate inflammatory arthritis. Ar...Keywords
Funding Information
- National Institutes of Health (AR-056468, CA-119342, HL-78631)
This publication has 45 references indexed in Scilit:
- Three‐dimensional MR mapping of angiogenesis with α5β1(αvβ3)‐targeted theranostic nanoparticles in the MDA‐MB‐435 xenograft mouse modelThe FASEB Journal, 2008
- The Concise Synthesis of a Key Intermediate for the Total Synthesis of Fumagillin, TNP-470, and OvalicinSynthesis, 2008
- Minute dosages of ανβ3‐targeted fumagillin nanoparticles impair Vx‐2 tumor angiogenesis and development in rabbitsThe FASEB Journal, 2008
- Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalizationMicrovascular Research, 2007
- Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial respondersRheumatology, 2007
- Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI‐2458Arthritis & Rheumatism, 2007
- New antiangiogenic strategies for the treatment of proliferative synovitisExpert Opinion on Investigational Drugs, 2005
- Angiogenesis as a target in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2003
- Effect of Blood Collection Technique in Mice on Clinical Pathology ParametersHuman Gene Therapy, 2002
- Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470New England Journal of Medicine, 1998